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Background and aims: The role of programmed cell death protein 1 (PD-1) and its 
ligands in the dysregulation of T helper immune responses observed in the inflammatory 
bowel disease (IBD) is unclear. Recently, a novel concept emerged that CD90+ colonic 
(myo)fibroblasts (CMFs), also known as stromal cells, act as immunosuppressors, and 
are among the key regulators of acute and chronic inflammation. The objective of this 
study was to determine if the level of the PD-1 ligands is changed in the IBD inflamed 
colonic mucosa and to test the hypothesis that changes in IBD-CMF-mediated PD-1 
ligand-linked immunosuppression is a mechanism promoting the dysregulation of 
Th1 cell responses.
Methods: Tissues and cells derived from Crohn’s disease (CD), ulcerative colitis (UC), 
and healthy individuals (N) were studied in situ, ex vivo, and in culture.
results: A significant increase in programmed death-ligand 1 (PD-L1) was observed in 
the inflamed UC colonic mucosa when compared to the non-inflamed matched tissue 
samples, CD, and healthy controls. UC-CMFs were among the major populations in the 
colonic mucosa contributing to the enhanced PD-L1 expression. In contrast, PD-L1 
expression was decreased in CD-CMFs. When compared to CD-CMFs and N-CMFs, 
UC-CMFs demonstrated stronger suppression of IL-2, Th1 transcriptional factor Tbet, 
and IFN-γ expression by CD3/CD28-activated CD4+ T  cells, and this process was 
PD-L1 dependent. Similar observations were made when differentiated Th1 cells were 
cocultured with UC-CMFs. In contrast, CD-CMFs showed reduced capacity to suppress 
Th1 cell activity and addition of recombinant PD-L1 Fc to CD-CMF:T  cell cocultures 
partially restored the suppression of the Th1 type responses.
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conclusion: We present evidence showing that increased PD-L1 expression sup-
presses Th1 cell activity in UC. In contrast, loss of PD-L1 expression observed in CD 
contributes to the persistence of the Th1 inflammatory milieu in CD. Our data suggest 
that dysregulation of the Th1 responses in the inflamed colonic mucosa of IBD patients 
is promoted by the alterations in PD-L1 expression in the mucosal mesenchymal stromal 
cell compartment.
Keywords: myofibroblasts, fibroblasts, programmed death-ligand 1, PD-l2, ulcerative colitis, crohn’s disease, 
inflammatory bowel diseases, Th1 cells
inTrODUcTiOn
Dysregulation of T helper (Th) cell responses in inflammatory 
bowel disease (IBD) is critically involved in colonic tissue dam-
age. Crohn’s disease (CD) is characterized by elevation of Th1 cells 
that express the Tbet transcription factor and produce IFN-γ (1). 
In contrast, for ulcerative colitis (UC) colonic mucosal produc-
tion of IFN-γ is either suppressed or comparable to normal tissue 
with an increase in Th2 cytokines IL-5 and IL-13 (2–4). While 
this disruption of balanced Th1/Th2 cell responses is among the 
important effector mechanisms contributing to the IBD patho-
physiology, the mechanisms responsible for this dysregulation 
remain unclear.
Innate immune cells are important regulators of the T  cell 
responses in the colon. TLR-dependent activation of dendritic 
cells and macrophages contribute to the dysregulation of T cell 
responses in IBD via increased production of inflammatory 
cytokines, such as TNF-α, IL-12, and IL-23 (5–8). In addition 
to the inflammatory cytokines, the B7 family of proteins also 
regulates T  cell responses (9, 10). Interactions of the B7 mol-
ecules programmed death-ligand 1 (PD-L1) and/or PD-L2 with 
programmed cell death protein 1 (PD-1) are known to control 
several tolerance checkpoints that prevent autoimmunity (11). 
Abnormities in PD-L1 and PD-L2 expression/signaling con-
tribute to several chronic infectious and inflammatory diseases, 
such as type 1 diabetes, rheumatoid arthritis, allergy, and chronic 
obstructive pulmonary disease. In these diseases, alterations in 
the expression and signaling of PD-1 and its ligands result in the 
dysregulation of Th1/Th2 responses and overall IFNγ produc-
tion (11–15).
Programmed death-ligand 1- and PD-L2-mediated signal-
ing by innate immune cells is crucial to the maintenance of the 
mucosal tolerance in the GI tract (16–18). Loss of PD-L1 signaling 
in the gut breaks CD8+ T cell tolerance to self-antigens and leads 
to severe autoimmune enteritis (18). The few reports on the role 
of PD-1 and its ligands in murine models of chronic colitis remain 
contradictory. PD-1 deficiency impairs induction of regulatory 
T  cells and promotes severe CD-like colitis (19), while PD-L1 
expression by DX5+NKT cells induces apoptosis of colitic CD4+ 
T cells (20). Suppression of PD-L1 with anti-PD-L1 monoclonal 
antibodies (mAbs) reduced chronic intestinal inflammation in 
the T cell transfer murine model of colitis (21), whereas use of a 
PD-L1Fc was shown to protect against T cell transfer-colitis (22). 
Furthermore, there is a worsening of DSS and TNBS acute colitis 
in PD-L1−/− mice compared to wild-type animals (23).
The intricate role of PD-L1 and PD-L2 in the dysregulation of 
Th cell responses in human IBD remains unclear and the sparse 
reports are contradictory. PD-L1 is upregulated in the intestinal 
epithelium, macrophages, and B cells in both forms of IBD (21, 24), 
yet expression of inducible PD-L1 appears to be impaired in 
CD-derived monocytes and ileal APCs (25, 26). Finally, recent 
reports indicate that while mAbs against PD-1 and anti-PD-L1 
are currently successfully used in clinics for treatment of several 
solid tumors, one of the main immune-related adverse effect 
(irAE) of the immune checkpoint blockade therapy is develop-
ment of chronic diarrhea and enterocolitis (27–29). A recent case 
report describes Crohn’s colitis-like phenotype as an irAE (30). 
Therefore, the role of these molecules in several types of IBD 
colitis warrants further investigation.
We previously reported that in the normal colonic mucosa, 
CD90+ stromal cells, otherwise known as colonic (myo)fibroblasts 
(CMFs) are a major cell type expressing PD-L1 and PD-L2 (16). 
CMFs act as major immunosuppressors under mucosal tolerance 
(16, 31, 32) and both molecules have been implicated in normal 
CMF-mediated suppression of activated CD4+ T cell proliferation 
(16). Normal CMFs suppress IFN-γ production by Th cells via 
PD-L1-mediated mechanism (32), but PD-L1/PD-L2 signaling is 
poorly characterized in IBD. Thus, PD-1 ligand signaling in IBD 
and in other types of colitis such as that associated with check-
point immunotherapy of cancer warrants more investigation.
In this report, we evaluated PD-L1 and PDL-2 expression 
in human IBD colonic mucosa and tested the hypothesis that 
changes in PD-1 ligand-mediated CMF signaling contributes to 
the dysregulation of Th1/Th2 cell responses in human IBD. We 
demonstrated that compared to normal or IBD non-inflamed 
colonic mucosa PD-L1, but not PD-L2, was strongly increased 
in UC and somewhat decreased in CD. We observed that PD-L1 
is critical to the CMF-mediated regulation of the Th1  cell 
cytokine production. Further, we found that increase in PD-L1 
by UC-derived CMFs contribute to the increased suppression 
of Th1  cell activity. In contrast, lower expression of PD-L1 by 
CD-CMFs contributed to the increase in the Th1 cell responses 
observed in CD. Taken together, our data identify CMFs as an 
important immunological component in colonic mucosa and 
suggest that changes in the CMF-mediated PD-L1 expression 
Abbreviations: α-SMA, α-smooth muscle actin; CD, Crohn’s disease; CMs, 
mucosal cells; CMFs, CD90+ myofibroblasts/fibroblasts; IBD, inflammatory 
bowel disease; UC, ulcerative colitis; PD-L1, programmed death-ligand 1; PD-1, 
programmed cell death protein 1.
TaBle 1 | Patient characteristics.
normal, control, 
N = 11
Uca,  
N = 21
cDa,  
N = 22
age
A2(18–40) 2 (18%) 9 (43%) 10 (45%)
A3 (≥40) 9 (82%) 12 (57%) 12 (55%)
sex
Male 5 (45%) 12 (57%) 12 (55%)
Female 6 (55%) 9 (43%) 10 (45%)
location
Ileum and cecum 9 (48%)
Right colon 2 (18%) 1 (5%) 1 (4%)
Transverse colon 3 (27%) 1 (4%)
Left colon 2 (18%) 2 (10%) 2 (8%)
Sigmoid/rectum 4 (37%) 5 (25%) 4 (16%)
Colon, mixed 13 (60%) 5 (20%)
Therapy
5-ASA n/a 3 (14%) 0
Corticosteroids n/a 2 (5%) 0
Immunomodulators/
corticosteroids
n/a 3 (14%) 0
5-ASA/corticosteroids n/a 0 (0%) 6 (27%)
Biologics n/a 0 (0%) 7 (32%)
Mix of biologics with 
corticosteroids/
immunomodulators
n/a 8 (43%) 5 (23%)
No treatment 11 (100%) 5 (24%) 4 (18%)
aAll patients included in this study had active disease, tissue inflammation was scored 
as moderate/severe.
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may be critical to the pathological dysregulation of the Th1 
immune responses in IBD.
MaTerials anD MeThODs
antibodies
Fluorochrome-conjugated and unconjugated murine anti-human 
α-smooth muscle actin (α-SMA, clone 1A4) monoclonal anti-
bodies (mAbs) were purchased from Sigma (St. Louis, MO, USA). 
Fluorochrome-conjugated forms of IgG1κ, IgG2a, isotype controls, 
and mAbs directed against human CD90 (clone 5E10) were 
purchased from BD Bioscience and eBioscience (San Diego, 
CA, USA). Fluorochrome-conjugated antibodies against human 
and murine CD4 (clone RPA-T4 and RM4-5, respectively), Tbet 
(clone eBIo4B10), isotype controls as well as mAbs against human 
PD ligands, PD-L1 (clone MIH1, clone 29E.2A3), and PD-L2 
(clone MIH18), antihuman IFN-γ (clone 45.B3) were obtained 
from eBioscience (San Diego, CA, USA) and BioLegend Inc., 
Alexa Fluor® (AF®) 488- and AF®633-labeled donkey anti-mouse 
IgG2a and IgG1κ (respectively), Zenon Mouse IgG antibodies 
labeling kits were purchased from Life Science Technology, Inc. 
(CA, USA). Functional grade anti-human IL-4 mAbs (clone 
B-S4), recombinant human IL-12 and IL-2 were purchased from 
ThermoFisher Scientific.
Tissue and cells
For CMF isolation, full thickness fresh human colonic mucosa 
samples were obtained from discarded surgical resections 
under UTMB and UNM Health Sciences Center approved IRB 
protocols #99-061 and #10-514, respectively. Surgical resection 
tissues from patients undergoing colectomy for UC, CD, or colon 
cancer (only normal margin used) were obtained. As discarded 
tissue, their use did not require informed consent, Endoscopic 
colonic biopsies were obtained after subject informed consent 
under UTMB approved human research protocol IRB# 03-392. 
Vulnerable populations (e.g., age less than 18) were not included 
in study. The information on the tissue samples used for cell isola-
tion in this study is provided in the Table 1. Total mucosal cell 
(CM) preparation was done as described previously (33). CMFs 
were isolated as previously described (32, 34). Studies were per-
formed with primary isolates of CMFs at passages 3–10. Standard 
MEM (ThermoFisher) + 10% FBS, 2 mM l-glutamine, 100 U/ml 
penicillin, 100 g/ml streptomycin, 1 mM sodium pyruvate was 
used for growth of both, CMF and T cells.
confocal Microscopy
Frozen human colonic step sections were fixed and immu-
nostained as described previously (16). Briefly, OCT frozen 
human colonic tissue sections were fixed in 1% paraformalde-
hyde for 20 min at room temperature, blocked with a PBS based 
blocking solution containing 2.5% normal murine serum and 
1 µg/ml of human BD Fc Block™ reagent (BD Bioscience, San 
Jose, CA, USA) for 15 min at room temperature. Unless otherwise 
indicated, samples were then incubated with AF546-conjugated 
anti–PD-L1 (clone MIH1) and AF488-conjugated anti-human 
CD90 (clone 5E10), anti-human α-SMA mAbs (clone 1A1) or 
AF647-conjugated anti-human EpCAM mAbs, or appropriate 
fluorochrome-conjugated mouse IgG1κ isotype control for 2  h 
at room temperature. Six time wash with Ca++Mg++PBS was 
performed before and after of the each of the described above 
steps. Samples were then mounted in SlowFade® Gold antifade 
reagent with DAPI (Life Science Technology, CA, USA). Confocal 
microscopy was performed with a Zeiss LSM510 META laser 
scanning confocal microscope (Carl Zeiss, Thornwood, NY, 
USA) (16). To quantify expression of the molecule of interest, the 
integrated density, area, and mean of fluorescence from at least at 
least 10 fields of in-focus images from each tissue were measured 
using ImageJ software (NIH, https://imagej.nih.gov/ij/). The 
Corrected Total Cell Fluorescence (CTCF) was then calculated 
according the method described by McCloy et al. (35) as follow-
ing CTCF = Integrated Density − (area of selected image × mean 
background fluorescence). Unless otherwise indicated, the fold 
change in the CTCF when compare to the average data from the 
from healthy normal colonic tissue images was calculated.
T cell isolation, activation,  
and Polarization
Peripheral blood mononuclear cells were prepared from the blood 
of healthy donors using density gradient centrifugation over 
Ficoll-Plaque Plus (Amersham Bioscience, Piscataway, NJ, USA) 
according to the manufacturer’s instructions. Naive human CD4+ 
T cells were then purified from these peripheral blood mononuclear 
cells by negative selection using a commercially available Naive 
CD4+ T-cell isolation kit II (Miltenyi Biotec, Auburn, CA, USA) 
according to the manufacturer’s instructions. Negative selection 
was chosen to avoid accidental activation of CD4+ T cells during 
4Beswick et al. Myo-/Fibroblast PD-L1 Signaling in IBD
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purification. Purified human naive CD4+ T cells were activated 
using Dynabeads™ Human T-Activator CD3/CD28 for T Cell 
Expansion and Activation kit (ThermoFisher Scientific, Grand 
Island, NY, USA) according to the manufacturer’s instructions. In 
some experiments CD45RA+ CD4+ T cells were polarized toward 
Th1 prior the use in a coculture experiments. For this purpose 
1 × 106 of CD45RA+ CD4+ T cell were cultured in standard MEM 
in presence of the T-Activator CD3/CD28 T Cell Expansion 
and Activation kit with a Th1 differentiation cocktail (rIL-12, 
25 ng/ml + anti-hIL-4, 5 µg/ml). On day 4 (expansion step) cells 
were harvested, counted, and resuspended at the concentration 
1 × 106 cell/ml and cultured in MEM media supplemented with 
the IL-2 (20 U/ml) and Th1 differentiation cocktail up to day 7. 
On day 7 anti-CD3/CD28 beads were removed according to the 
T-Activator CD3/CD28 for T Cell Expansion and Activation kit 
instruction and described above procedure was repeated for total 
of 14 days. The purity of isolated CD45RA+ CD4+ T cells (>98%) 
and efficiency of the Th1 polarization was controlled by flow 
cytometry prior the use of cells in the CMF-T cell cocultures. In 
some experiments, T cells were labeled with Carboxyfluorescein 
Diacetate Succinimidyl Ester (CFSE) using the cell trace™ CFSE 
cell proliferation kit (Molecular Probes, Inc., Eugene, OR, USA) 
according to the manufacturer’s instructions.
cMF:T cell coculture experiments
Primary adherent CMFs were growth until 90% confluency in 
24-well plates (7-day culture) in a standard MEM media, then used 
in the CMF:T cell coculture experiments. Activated or unprimed 
CD4+ T cells were cocultured in 24-well plates in the presence or 
absence of CMFs in ration 2.5:1, respectively. mAbs against the 
studied co-stimulatory molecules, PD-L1 Fc human fusion protein 
or isotype controls were added to the cocultures (when necessary) 
at a final concentration 1 µg/ml. Cocultures or control monocul-
tures were then incubated for 5 days maximum at 37°C in 5% CO2.
Primary cMFs Transfection With small 
interfering rna (sirna)
Small interfering RNA technology was used to knockdown 
expression of PD-Ls molecules in human primary CMF isolates 
as described previously (16). Breifly, negative siRNA controls are 
included in each experiment. Stealth siRNAs Set of three siRNA 
probes to the conservative domains of PD-L1, PD-L2, or negative 
siRNA control were purchased from Thermo Fisher Scientific. 
Transfection of CMFs was performed using Human Dermal 
Fibroblast Nucleofector kit according to the manufacturer instruc-
tion (Lonza, Allendale, NJ, USA). The efficiency of the downregu-
lation of the PD-L1 or PD-L2 expression by specific siRNA set was 
controlled by real-time RT-PCR and flow cytometry.
real-Time rT-Pcr
Real-time RT-PCR analysis was performed according to the 
two-step RT real-time PCR protocol as previously described 
(36). The appropriate assays-on-demand™ gene expression mix 
(ThermoFisher Scientific) for human the gene of interest and 
housekeeping gene (a 20× mix of unlabeled PCR primers and 
TaqMan® MGB probe, FAM™ dye-labeled) and 2 µl of cDNA were 
added to the PCR reaction step. The reactions were carried out in 
a 20-µl final volume using a Bio-Rad Q5 real-time PCR machine 
according to the following protocol: 2 min at 50°C, 10 min at 95°C 
(1 cycle), and 15 s at 95°C and 1 min at 60°C (45 cycles).
Flow cytometry
Single- and multi-color immunostaining were performed accord-
ing to standard eBioscience surface and intracellular FACS stain-
ing protocols. Cells were analyzed by flow cytometry using LSRII 
cytometers (BD Biosciences) per the manufacturer’s procedure. 
Area, height, and width parameters for forward and side scatters 
(FSC and SSC, respectively) were used to discriminate single live 
cells. An additional gate was set up based on the negativity for the 
fixable viability dye eFluor® 780 (eBIoscience), which was added 
during the surface marker staining to exclude dead cells from the 
analysis. Flow cytometry data were analyzed using FACSDiva 6.3 
(Becton Dickinson) software.
cytokine Production
For the analysis of cytokine production in the freshly obtained 
colonic specimens, the mucosa tissue was cut to ~8  mg pieces 
and incubated in complete RPMI for 12  h. Supernatants were 
collected and cytokines were measured by multiplex bead array 
(EMD Millipore, Bellerica, MA, USA) using a Luminex™200 
according to the instructions from manufacture. Cytokine analy-
sis was also performed on conditioned media from CMF:T cell 
cocultures and the cytokine profiles in coculture supernatants 
were analyzed as described above.
statistical analysis
The results were expressed as the mean ± SE of data obtained from 
at least three independent experiments done with at least dupli-
cate sets per experiment. Unless otherwise indicated, differences 
between means were evaluated by one way ANOVA in GraphPad 
Prism 5. Values of P < 0.05 were considered statistically significant.
resUlTs
PD-l1 mrna level is increased in colonic 
Mucosa From Uc, but Decreased in cD 
colitis
Despite recent evidence pointing to a critical role of PD-L1 and 
PD-L2 in the maintenance of gut tolerance, their expression 
within the two major subtypes of IBD remains contradictory. 
Therefore, we examined the level of PD-L1 and PD-L2 mRNA 
expression in colonic mucosa from adult patients with chronic 
UC and CD colitis. A significant increase in total PD-L1 mRNA 
expression in UC colonic mucosa was noted when compared to 
normal healthy controls. By contrast, the total tissue PD-L1 mRNA 
expression was decreased in CD (Figure 1A). A similar observa-
tion was made using in situ analysis: PD-L1 protein was mostly 
upregulated in both UC mucosal lamina propria (LP) and to a 
less extent in epithelium but decreased in CD LP compared to the 
healthy controls (Figure 1B). In contrast, no change in PD-L2 was 
observed in either IBD type when compared to normal controls 
(Figure  1C). Analysis of colonic tissue obtained from surgical 
FigUre 1 | Programmed death-ligand 1 (PD-L1) is increased in ulcerative colitis (UC), but decreased in Crohn’s disease (CD) colonic mucosa. (a) PD-L1 mRNA 
levels in UC and CD colonic mucosa were compared to normal tissue controls obtained from healthy individuals (real-time RT-PCR analysis). The means ± SEM are 
shown as the results of duplicates of each tissue sample, n = 11 per group. (B) PD-L1 protein expression in situ was increased in UC and somewhat decreased in 
CD. In these experiments, frozen colonic tissue sections were stained with DAPI to identify cell nuclei (blue) and anti-PD-L1 monoclonal antibodies (clone MIH, in 
red) and analyzed by confocal microscopy (63×). A representative cross sections and summary of fold changes in the corrected total cell fluorescence (CTCF) of 
PD-L1 expression in UC, CD, and normal human colonic mucosa (the means ± SEM are shown, n = 10 per group) are shown, L, lumen; LP, lamina propria, 
*p < 0.05. (c) PD-L2 mRNA levels in UC and CD colonic mucosa were compared to normal tissue controls obtained (real-time RT-PCR analysis). The means ± SEM 
shown are the results of duplicates of each tissue sample, n = 11 per group. (D) PD-L1 mRNA levels in UC and CD inflamed colonic mucosa was normalized to its 
matched, non involved tissue controls (real-time RT-PCR analysis). The means ± SEM shown are the results of duplicates of each tissue sample, n = 20 per group.
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resections demonstrated that PD-L1 expression was significantly 
upregulated in the inflamed mucosa from UC and downregulated 
in CD when compared to the non-inflamed mucosal samples 
from the same subject (i.e., matched samples) (Figure 1D). These 
observations suggest that changes in PD-L1, but not PD-L2 may 
be contributing to the immunopathogenesis of IBD.
expression of PD-l1 by cD90+ 
Mesenchymal stromal cells Depends  
on the subtype of iBD: high in Uc, but 
low in cD
CD90+ stromal (myo)fibroblasts (CMFs) are abundant in the 
normal and IBD mucosal LP and can be identified in humans 
(but not mice) by surface expression of the mesenchymal line-
age marker CD90 (33, 37). Previously, we reported that CMFs 
are the major cell type expressing PD-L1 in colonic LP under 
homeostasis (16). Thus, to examine cellular compartmentaliza-
tion of PD-L1 expression in inflamed IBD tissue, we performed 
immunostaining followed by flow cytometry analysis of fresh 
single cell suspension preparations of whole layer of human 
colonic mucosa (epithelium and LP). We observed a significant 
increase in PD-L1+CD90+ CMFs in UC. In contrast, a decrease 
in PD-L1 expressing CMFs was noted in the CD colonic mucosa 
(Figures 2A,C). Interestingly, while not reaching significance, an 
overall relative loss of CMFs was occasionally observed in CD 
mucosa (Figure 2A). The last one may be due to degeneration of 
the pericryptal CMFs, which was previously observed by us in 
FigUre 2 | The number of programmed death-ligand 1 (PD-L1) expressing CD90+ colonic stromal cells (CMFs) is increased in ulcerative colitis (UC), but decreased 
in Crohn’s disease (CD) colitis. Freshly digested Normal (N), UC, and CD colonic mucosal single cell suspensions (CM) were prepared and immunostained and 
analyzed by multi-color flow cytometry. Live events were gated and mucosal cells (CMs) were analyzed for the PD-L1 expression. (a) A representative density plot 
for the flow cytometry analysis for the expression of PD-L1 by CD90+ CMFs. (B) A representative density plot for the flow cytometry analysis for the expression of 
PD-L1 by EPCAM+ cells out of CD90− colonic mucosal (CD90− CM) cells. (c) Summary of the PD-L1 expression by CD90+ EpCAM− cells (CMFs) CD90− EpCAM+ 
cells (epithelial cells) and CD90−EpCAM− professional immune cells in normal, UC-CM, and CD-CM preparations (flow cytometry analysis). Values are expressed as 
a mean of percentage positive cells ± SD, n = 9 per group.
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IBD tissue (38). Analysis of IBD colonic tissue in situ confirmed 
the flow cytometry observations that the PD-L1 expressing 
CD90+ cell population is strongly increased in the inflamed UC 
colonic mucosa (Figure 3, formation of yellow-orange color on 
merged images). In contrast, a decrease in PD-L1 expression 
In the CD90+ cell population was seen in CD (Figures  3A,B). 
We observed a moderate increase in PD-L1+EpCAM+ epithelial 
cells in UC. Epithelial PD-L1 was increased, but to a lesser extent 
in CD than that the increase seen in UC, suggesting that a redis-
tribution of PD-L1 expression (decrease in LP cells and slight 
increase in epithelial cells) may occur in CD (Figures  2B,C). 
The flow cytometry observations were confirmed by tissue 
FigUre 3 | (a) The number of programmed death-ligand 1 (PD-L1) expressing CD90+ mesenchymal cells is increased in ulcerative colitis (UC) and decreased in 
Crohn’s disease (CD) colonic mucosa. Confocal microscopy analysis of a representative cross sections of UC, CD, and normal human colonic mucosa (n = 10 per 
group) were performed. Cell nuclei (in blue) were stained with DAPI. CMFs may be identified by morphology, lamina propria location, and staining with anti-human 
CD90 monoclonal antibodies (mAbs) conjugated to AF®488 (clone 5E10, in green). PD-L1 staining (in red) was performed using AF®633-labeled anti-PD-L1 human 
mAbs (clone MIH1). Co-localization of PD-L1 within CD90+ CMFs shown in yellow-orange (arrow) on merged images. (B) Summary of changes in the PD-L1 
expression by CD90+ CMFs in situ. Image J software was used for the quantification analysis as described in Section “Materials and Methods.” Data were 
expressed as means ± SEM of percentage of the changes in the count of corrected total cell fluorescence (CTCF) of PD-L1 positive CD90+ cells (yellow-orange 
color formation) over total CD90+ CMFs (both, green and yellow-orange stained cells), n = 10 per group, *p < 0.05. (c) Changes in PD-L1 expression in 
mesenchymal stromal cells of inflamed inflammatory bowel disease colonic mucosa are mainly associated with α-smooth muscle actin (α-SMA+) myofibroblasts. 
Confocal microscopy images of two representative cross sections from UC, CD, and normal human colonic mucosa (n = 7 per group) are shown. Activated 
fibroblasts(myofibroblasts), were detected by anti-α-SMA mAb (green), and epithelial cells were identified with anti-EpCAM mAb (in blue). Co-localization of PD-L1 
with epithelial cells and α-SMA+ myofibroblasts results in formation of magenta and yellow-orange color, respectively, on merged images. (D) Summary of the 
changes in the PD-L1 expression by α-SMA+ cells (a.k.a. myofibroblasts) in situ. Image J software was used for the quantification analysis. Data were expressed as 
means ± SEM of percentage of the changes in the count of CTCF of PD-L1 positive α-SMA+ cells (yellow-orange color formation) over total α-SMA+ myofibroblasts 
(both, green and yellow-orange stained cells), n = 7 per group, *p < 0.05.
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immunostaining in situ followed by confocal microscopy analy-
sis (Figure 3C, formation of magenta color on merged images). 
Additionally, some increase in PD-L1 expressing CD90− EpCAM− 
CMs were observed in both forms of IBD (Figure 2C).
Taken together, our data suggest that epithelial cells and 
stromal cells (CMFs) respond to the IBD chronic inflammation 
with changes in PD-L1 expression. Further, colonic LP PD-L1 
is differentially expressed in UC (increased) vs CD (decreased). 
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Finally, CD90+ mesenchymal cells (CMFs) are the cell phenotype 
associated with differential expression of PD-L1 in the two major 
forms of IBD.
changes in PD-l1 expression in iBD-
Derived colonic Mesenchymal stromal 
cells are Mostly associated With α-sMa+ 
Myofibroblasts
To further examine the CD90+ population expressing PD-L1, 
staining was undertaken using the myofibroblast marker, 
α-SMA. CD90 is a pan-mesenchymal lineage marker in the 
human identifying both mesenchymal stem cells (MSCs), fibro-
blasts, and myofibroblasts (37, 39). Recent publications provide 
strong evidence for a slow cycling, α-SMA negative tissue MSC 
population in the LP of intestinal mucosa (40). In contrast, 
α-SMA marks mostly differentiated LP mesenchymal cells 
otherwise known as myofibroblasts. Thus, next, we investigated 
PD-L1 expression by α-SMA+ CMFs in IBD inflamed colonic 
mucosa compared to the normal mucosa obtained from normal 
healthy controls. Co-immunostaining of UC tissue for α-SMA 
(in green) and PD-L1 (in red) demonstrated a strong increase in 
PD-L1 expression mostly co-localized with α-SMA+ myofibro-
blasts (Figures 3C,D). Analysis of α-SMA+ CMFs in CD colitic 
mucosa demonstrated that PD-L1 expression was either 
decreased in comparison to the normal tissue or completely lost 
(Figures 3C,D).
changes in PD-l1 expression Modify 
iBD-cMF-Mediated suppression of cD4+ 
T cell Proliferation
(Myo)fibroblasts isolated from normal (N-) and cancer human 
mucosal GI tissues maintain their phenotype and activity in cul-
ture (16, 41, 42). Thus, to assess the functional significance of the 
changes in PD-L1 expression by colonic MFs (CMFs) in IBD, we 
isolated CMFs from CD and UC colonic mucosa and compared 
them to N-CMFs. Both UC- and CD-CMF isolates maintained 
their differential high or low profile of PD-L1 expression in 
culture as determined by mRNA and surface protein analysis 
(Figures 4A,B). In contrast, no significant changes were noted in 
surface PD-L2 expression on these cells (Figure 4C).
Previously, we reported that N-CMFs-suppress activated 
T effector cell proliferation and IL-2 (a cytokine produced by 
actively proliferating T cells) via a PD-L1- and PD-L2-mediated 
mechanism (16). Thus, we next examined how changes in PD-L1 
expression modify the capacity of IBD-CMFs to suppress activated 
CD4+ T cell proliferation. In these assays, CD45RA+CD4+ T cells 
were isolated from peripheral blood mononuclear cells of healthy 
volunteers, activated with anti-CD3/anti-CD28 mAbs and then 
incubated in the presence of UC-, CD-, or N-CMFs. We observed 
that UC-CMFs exhibited stronger suppression of IL-2 produc-
tion when compared to N-CMFs, although this suppression did 
not reach statistical significance. In contrast, CD-CMFs exhibit 
significantly less suppression of T  cell proliferative response 
(Figure 4D and Figure S1 in Supplementary Material). The N- and 
UC-CMF-mediated suppressive capacity was PD-L1 dependent 
since addition of PD-L1 blocking antibodies, but not isotype con-
trol, reversed suppression of IL-2 production in these cocultures 
(Figure 4D). While the mechanisms implicated in the differential 
impairment of PD-L1 expression by IBD-derived CMFs are 
currently unknown, these data suggest that UC-derived CMFs 
suppress activated T cell proliferation as we previously observed 
for N-CMFs (16). In contrast, CD-CMF-mediated suppression 
is significantly decreased, possibly due to the combination of the 
decreased expression of PD-L1 in conjunction with other not yet 
well characterized factors that may enhance IL-2 production by 
T cells.
changes in PD-l1 expression Modify 
iBD-cMF-Mediated regulation of Tbet 
and iFn-γ Production by cD3/cD28-
activated and Differentiated Th1 cD4+  
T cells
Programmed death-ligand 1 is critical to the regulation of the 
balance between Th1 and Th2 type immune responses in  vivo 
(11). Previously, we have shown that N-CMFs suppress IFN-γ 
production by activated T cells in a PD-L1-dependent manner 
(32). An increase in the IFN-γ-producing Th1 cells in CD LP and 
a decrease in UC LP have been recently observed by several inves-
tigators (43–45). We also observed an increase in IFN-γ levels in 
the inflamed mucosa of patients with CD colitis (Figure 5). Next, 
we determined how changes in PD-L1 expression within IBD-
CMFs modify their capacity to regulate Th1/Th2 type responses 
in activated CD4+ T  cells. Priming of activated T  cells with 
UC-CMFs led to stronger suppression of Tbet mRNA expression 
(Th1 response) in the T  cells than did priming with N-CMF. 
Similar data were observed for IFN-γ expression (Figure  6A). 
In contrast, priming of activated T  cells with CD-CMFs failed 
to suppress Th1 type responses (Figure  6A). These data were 
confirmed on the protein level by flow cytometry: UC-CMFs 
demonstrated stronger suppression of the IFN-γ+Tbet+ cells when 
compared to N-CMFs, while CD-CMF-mediated suppression of 
the IFN-γ+Tbet+ was significantly reduced or lost (Figure 6B). 
These findings were confirmed by measuring IFN-γ secretion by 
bead array (Figure 6C).
PD-l1, but not PD-l2, is critically involved 
in the alteration of cMFs-Mediated 
suppression of Th1 Type responses  
in iBD
Blocking PD-L1 with specific antibodies significantly reduced 
the ability of N- and UC-CMFs to suppress both Tbet and IFN-γ 
mRNA expression by cocultured T  cells (Figure  7A). Since 
activated T cells are capable of expressing low levels of PD-L1, we 
then confirmed the primary role of CMFs using PD-L1 specific 
siRNA (Figure 7B). A contribution of PD-L2 to the suppression 
of the Th1 type responses was previously observed in the animal 
models of airway hyperreactivity and in infectious diseases 
(46, 47). Because both N- and IBD-derived CMFs expressed basal 
levels of PD-L2 and PD-L1, to determine the relative contribu-
tion of either ligand to the CMF-mediated suppression of Th1 
FigUre 4 | An increase in surface programmed death-ligand 1 (PD-L1) by UC-CMFs and a decrease by CD-CMFs modify cell-mediated suppression of IL-2 
production byCD3-/CD28-activated CD4+ T cell IL-2 production. (a) PD-L1 mRNA (real-time RT-PCR analysis) and (B) surface protein (flow cytometry analysis) 
expression was increased in 6–7 days, 90–100% confluent primary cultures of UC-CMFs, but decreased in CD-CMFs when compared to N-CMFs. Representative 
flow cytometry histogram and summary of the surface PD-L1 expression shown on panel (B). The means ± SEM are shown, n = 8 per group. (c) PD-L2 surface 
expression on primary UC-, CD-, and N-CMFs (flow cytometry analysis); the means ± SD are shown, n = 8 per group. (D) CMFs were cocultured with allogeneic 
CD3-/CD28-preactivated naive CD4+ T cells (Act T cells) at a ratio of 1:2.5 for 72 h in 24-well plates. PD-L1 blocking mAbs (clone MIH1) or isotype controls were 
added in the concentration 1 µg/ml. IL-2 production was analyzed using singleplex cytokine analysis. The means ± SD are shown, n = 5 allogeneic donor pairs per 
group, two experimental replicates each.
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FigUre 5 | IFN-γ expression is decreased in the colonic mucosa of ulcerative colitis (UC) but increased in Crohn’s disease (CD) when compared to normal controls. 
In these experiments, frozen colonic tissue sections were stained with DAPI to identify cell nuclei (blue) and anti-IFN-γ monoclonal antibodies (clone 4S.B3, in red) 
and analyzed by confocal microscopy, objective used is 63×. (a) Representative cross sections of UC, CD, and normal human colonic mucosa and (B) summary of 
fold changes in the corrected total cell fluorescence (CTCF) of PD-L1 expression in UC, CD, and normal human colonic mucosa (the means ± SEM are shown, 
n = 5 per group), L, lumen; LP, lamina propria.
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immune response, experiments were included studies in which 
PD-L2 was silenced using specific siRNA. Since silencing of 
PD-L2 in CMFs did not significantly change the CMF-mediated 
suppression of the IFN-γ+Tbet+ cells (Figure 7B), we concluded 
that CMF-mediated suppression of the Th1 type responses was 
specific to PD-L1, but not PD-L2. We next determined if compen-
sation of this lack of the immune checkpoint molecule by using 
PD-L1 hIgG1 fusion protein (PD-L1Fc) which may bind to the 
Fc receptor on CD-CMFs, compensates to these cells decreased 
PD-L1 expression, and might restore the ability of CD-CMFs 
to suppress activated CD4+ T cells since CD-CMFs express low 
levels of PD-L1. Indeed, addition of the PD-L1 Fc, but not IgG 
Fc (as a control), to the CD-CMFs: activated T  cell cocultures 
resulted in partial restoration of CD-CMF-mediated suppression 
of the Tbet mRNA expression and IFN-γ production by cocul-
tured T cells (Figure 8A).
Finally, the effect of CMFs on T cells polarized toward a Th1 
phenotype was examined. In these experiments, Th2 transcrip-
tional factor GATA2 was used to assess the efficiency of the 
naïve CD4+ T  cells polarization toward Th1. When compared 
to N-CMFs, UC-CMFs strongly suppressed the number of 
IFN-γ+Tbet+ Th1 cells. In contrast, CD-CMFs did not suppress 
Th1  cells (Figure  8B). The N- and UC- CMFs-mediated sup-
pression of Tbet expression in Th1  cells was partially reversed 
when anti-PD-L1 blocking mAbs were added to the cocultures 
(Figure 8B).
Taken together, these data suggest that increased PD-L1 
expression by CMFs in UC very likely contributes to the overt 
suppression of a Th1 type response. In contrast, downregulation 
of PD-L1 in CD-CMFs is likely to be an important contributor to 
the pathological increase in the inflammatory Th1 type responses 
observed in CD colonic mucosa.
DiscUssiOn
Dysregulation of Th cell immune responses is a hallmark of IBD 
immunopathogenesis (2–4). However, the mechanisms involved 
in this dysregulation are far from elucidated. Recent studies in 
other diseases suggest that aberrations in PD-L1 and/or PD-L2 
expression contribute to alterations in Th immune responses 
(46–49). However, very little is known about the role of these 
molecules in IBD. Data presented here suggest that aberrations 
in PD-L1 expression by colonic CMs may play a critical role in 
the imbalance in Th1/Th2 responses, and may contribute to the 
persistence of the chronic inflammation in IBD colitis. In other 
tissues and diseases, such as murine Fasciola hepatica infection 
and asthma, PD-L2 has been reported to negatively regulate 
Th1-mediated immunopathology (46) and promote Th2 type 
FigUre 6 | UC-CMFs demonstrate strong suppression of Th1 type responses in the CD3/CD28-activated CD4+ T cells, while CD-CMF-mediated suppression was 
significantly reduced. (a) Tbet and IFN-γ mRNA expression by the T cells was analyzed using real-time RT-PCR analysis. The means ± SEM are shown, n = 4 
allogeneic donor pairs per group, two experimental replicates each. (B) The percentage of the T cells expressing Th1 transcription factor Tbet and the Th1 cytokine 
IFN-γ was analyzed using intracellular immunostaining for flow cytometry. The means ± SED are shown, n = 8 allogeneic donor pairs per group. (c) IFN-γ 
production was analyzed using singleplex cytokine analysis. The means ± SD are shown, n = 8 allogeneic donor pairs per group, two experimental replicates each.
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response (48), respectively. While we previously reported that 
PD-L2 contributes to the N-CMF-mediated suppression of T cell 
proliferation (16), here we show that PD-L2 is not critical to the 
CMF-mediated suppression of the Th1 type responses. An addi-
tional novel observation here is that, in contrast to a moderate 
upregulation of PD-L1 in both CD and UC lamina epithelium 
and other non mesenchymal cells, only CD90+ LP cells showed 
differential change in the expression of PD-L1 between these two 
subtypes of IBD. This observation suggests that changes in the 
immune regulatory function of CD90+CMFs may be functionally 
specific to the IBD subtype.
While several publications have reported an increase in PD-L1 
expressing cells in IBD tissue (21, 23, 24), we have shown here 
that both PD-L1 mRNA and protein are differentially changed 
in IBD colitis: highly upregulated in UC and downregulated in 
CD. In contrast to other chronic diseases linked to the disrup-
tion of Th1/Th2 balance (46, 48), we did not observe significant 
changes in PD-L2 expression or its distribution within IBD 
colonic mucosa. PD-L1 has been shown also by others to suppress 
IFN-γ production by Th1 cells and promote Th2 immune responses 
(13, 49), and our studies concur in proposing in PD-L1 expression 
may be involved in the dysregulation of the Th helper responses 
observed in IBD.
In contrast to the study by Kanai et  al. (21), we did not 
observe significant upregulation of PD-L1 in CD tissue, perhaps 
because we studied only active inflamed Crohn’s colitis, while 
this group examined tissues from CD stenosing ileitis (21). There 
is discordance as to the predominant cells expressing PD-L1 in 
IBD: macrophages and dendritic cell expression was noted in 
inflamed UC and CD colon (21) but in the IBD epithelium by 
others (24). However, those studies where performed mostly 
by flow cytometry, where selective enrichment and gating of 
the professional immune cells did not include CMF analysis. 
Furthermore, a deficiency in professional antigen-presenting 
cells PD-L1 induction was reported in small intestinal lymphoid 
patches in CD (25, 26). We confirmed that PD-L1 was moderately 
increased in the UC and CD epithelial cells as has been previously 
seen by Nakazawa et al (24). However, we demonstrated herein 
FigUre 7 | CMF-mediated suppression of Th1 type responses depend on the level of expression of the programmed death-ligand 1 (PD-L1), but not PD-L2.  
(a) N-, UC-, and CD-CMFs were cocultured with allogeneic CD3/CD28-activated naive CD4+ T cells in presence/absence of PD-L1 blocking monoclonal antibodies 
(clone MIHI) or isotype control. Tbet and IFN-γ mRNA expression by the T cells was analyzed using real-time RT-PCR analysis. The means ± SEM are shown, n = 4 
allogeneic donor pairs per group, two experimental replicates each. (B) N-, UC-, and CD-CMFs transfected or not with small interfering RNA (siRNA) specific to 
PD-L1, PD-L2, or siRNA control were cocultured with allogeneic CD3/CD28-preactivated naive CD4+ T cells. The percentage of the T cells expressing Tbet and  
IFN-γ was analyzed using intracellular immunostaining followed by flow cytometry. The means ± SD are shown, n = 4 allogeneic donor pairs per group, two 
experimental replicates each.
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that a robust increase in PD-L1 expression in UC active inflamed 
mucosa is highly associated with cells bearing the mesenchymal 
phenotype, while a decreased PD-L1 expression is noted in these 
cells in CD.
Mesenchymal stem cells are believed to be major progeni-
tors of CMFs (37, 40) and share the CD90 marker with CMF. 
MSC express PD-L1 (50, 51) and a recent study suggested that 
there may be tissue-resident MSC in the intestinal mucosa (40). 
Therefore, the possibility that some fraction of PD-L1+ cells may 
be MSCs cannot be excluded. However, staining for α-SMA, a 
marker of differentiated MSC, demonstrated that, at least in 
UC, the majority of PD-L1 expressing cells were identified as 
myofibroblasts. Further, the reduction of PD-L1 in CD may serve 
as a scientific rationale for the use of “PD-L1 competent” MSCs 
for the treatment of perianal CD where the major objective is to 
deposit these stem cells locally in fistulizing tracts to suppress the 
local inflammatory responses (52).
In addition to intestinal fibroblasts and myofibroblasts, PD-L1 
expression also has been reported on other tissue fibroblast-like 
mesenchymal stromal cells, including hepatic stellate cells and 
decidual stromal cells (53). However, the role of the stromal 
cell-mediated PD-L1 signaling during chronic inflammatory 
diseases in those tissues is unclear. Herein, we demonstrated that 
the increase in PD-L1 expression by UC-CMFs and the decrease 
on CD-CMFs resulted in the respective increase and decrease 
of the CMF-mediated capacity to suppress Th1 type responses 
in both recently activated and fully differentiated Th1  cells 
demonstrating the importance of CMFs in the regulation of Th 
cell responses in these diseases. A disruption of Treg function 
has been observed in the IBD mucosa. We and other previously 
FigUre 8 | (a) CD-CMFs were cocultured with allogeneic CD3/CD28-preactivated naive CD4+ T cells in presence/absence of the PD-L1Fc or IgG Fc control. IFN-γ 
expression (real-time RT-PCR) and secretion (singleplex cytokine analysis) were analyzed. The means ± SEM are shown, n = 3 allogeneic donor pairs per group, two 
experimental replicates each. (B) Th1 cells were differentiated from CD4+ naïve T cells and cocultured with N-, UC-, and CD-CMFs in presence/absence of the 
PD-L1 blocking monoclonal antibodies or isotype control. Percentage of the T cells expressing the Th1 transcription factor Tbet was analyzed by flow cytometry. 
The means ± SED are shown, n = 7 allogeneic donor pairs per group.
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observed that PD-L1/PD-1 signaling also contributes to the 
induction of Treg (18, 54). In our previous study, we showed 
that while N-CMF induce generation of the suppressive Tregs, 
IBD-CMFs lose their capacity to generate fully suppressive Tregs 
(31). However, PD-L1-mediated signaling had only limited 
contribution to CMFs capacity to induce Treg (31). Further 
studies are needed to understand contribution of IBD-CMFs 
and its immune checkpoint repertoire to the dysregulation of the 
other type of the Th cells (e.g., Th17 cells) that contribute to the 
immunopathogenesis of the IBD.
Previously, we reported that basal CMF levels of PD-1 ligands 
are critical to the colonic mucosal tolerance (16, 32). Herein, we 
present evidence that increased PD-L1 expression suppresses 
Th1 cell activity in UC. In contrast, loss of CMF PD-L1 expres-
sion in the CD mucosal LP may contribute to the persistence of 
the Th1 inflammatory milieu in CD. Taken together, our findings 
suggest that while signaling through both PD-1 ligands is critical 
to the maintenance of the homeostatic tolerance, changes in the 
PD-L1 expression by IBD-CMFs may be among the critical fac-
tors supporting dysregulation of the Th1 type responses in both 
CD and UC. While further studies are required to understand 
the mechanism of these differential changes in the expression 
of PD-L1 in IBD-derived CMFs, and the mechanism of PD-L1’s 
effect on Th cell type, our data strongly support the significance 
of overall PD-L1 and especially CMF-mediated signaling in the 
immunopathogenesis of IBD. Further, while targeting PD-1 
and its ligands has emerged as a successful therapeutic modal-
ity for the treatment of melanoma, renal, and lung cancers 
(55–57), one of the major irAEs of immune checkpoint therapy 
is development of diarrhea and colitis (58). The mechanism of 
this colitis remains to be clarified. Our data support the idea 
that PD-L1 expression may be a candidate for the development 
of novel diagnostic tissue biomarkers to differentiate CD and 
UC and this molecule could be considered a therapeutic target 
for IBD.
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